Plasmodium falciparum DNA and other macromolecules

Plasmodium falciparum DNA and other macromolecules represent a broad category of molecular targets essential for the survival, replication, and pathogenesis of the malaria parasite (PubMed: 30634231). DNA serves as the template for genetic inheritance and protein synthesis, making it a critical site for drugs that intercalate or cause oxidative damage, such as certain aminoquinolines (PubMed: 6250527). The term "other macromolecules" encompasses a wide array of proteins, lipids, and carbohydrates that maintain the parasite's structural integrity and metabolic processes, including the digestion of host hemoglobin (DrugBank: DB00608). Many traditional antimalarial agents, including chloroquine and quinine, were historically described as targeting DNA or broadly interfering with macromolecular synthesis before more specific mechanisms, like heme detoxification inhibition, were identified (PubMed: 12117798). Modern understanding highlights that drugs like artemisinins act by generating reactive radicals that non-specifically alkylate various parasite proteins and lipids, leading to rapid parasite death (Nature: 10.1038/nature16468). Consequently, this target group is central to the efficacy of several major classes of antimalarials, though its non-specific nature often complicates the precise mapping of drug-target interactions. Therapeutic challenges associated with these targets include the rapid emergence of resistance mutations in genes like pfcrt and pfmdr1, which alter drug accumulation or target sensitivity (PubMed: 29155627). Despite the broad nature of this classification, it remains a foundational concept in antimalarial pharmacology and drug development.

Other names

Plasmodium falciparum genomeP. falciparum proteinsP. falciparum lipidsParasite macromolecules

DNA intercalation, alkylation of proteins and lipids, and inhibition of macromolecular synthesis (PubMed: 6250527, Nature: 10.1038/nature16468).